NEW YORK (GenomeWeb News) — Protein therapy products maker GenOdyssee today said it will provide Baxter with its technology, intellectual property, and integrated processes.
 
Under the agreement, Baxter will use these platforms to discover "novel blood clotting factors" in the course of its hemophilia research, and will develop and market any "commercially viable products" resulting from the partnership.
 
Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

The Wall Street Journal looks into the cost of new gene therapies.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.